HSIC241115P80000
- 10.30
- 0.000.00%
Henry Schein Newsroom
A Quick Look at Today's Ratings for Henry Schein(HSIC.US), With a Forecast Between $74 to $83
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
Henry Schein Is Maintained at Outperform by Barrington Research
Henry Schein Price Target Maintained With a $82.00/Share by Barrington Research
Henry Schein Analyst Ratings
Henry Schein: Buy Rating Affirmed Amid Strong Profitability and Strategic Cost Management
A Quick Look at Today's Ratings for Henry Schein(HSIC.US), With a Forecast Between $55 to $83
Henry Schein (HSIC) Gets a Buy From Piper Sandler
Henry Schein's Sell Rating: Internal Sales Weakness and Valuation Concerns Amidst Cybersecurity and Market Challenges
Evercore ISI Sticks to Their Hold Rating for Henry Schein (HSIC)
BofA Securities Maintains Henry Schein(HSIC.US) With Sell Rating
Bank of America Securities Sticks to Their Sell Rating for Henry Schein (HSIC)
CFRA Initiates Henry Schein(HSIC.US) With Sell Rating, Announces Target Price $67
Henry Schein Analyst Ratings
Evercore Maintains Henry Schein(HSIC.US) With Hold Rating, Raises Target Price to $74
Evercore ISI Adjusts Price Target on Henry Schein to $74 From $70, Maintains In Line Rating
Henry Schein Analyst Ratings
Barrington Research Maintains Outperform on Henry Schein, Maintains $82 Price Target
Barrington Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $82
Buy Rating Affirmed for Henry Schein Amid Aggressive Share Repurchase and Strategic Growth Initiatives